Table 5.

Ongoing first-line phase III clinical trials involving immune checkpoint inhibitors with combination regimens

Trial name	GOG3015/ENGOT OV39	FIRST trial/ENGOT Ov-44	DUO-O/ENGOT Ov-46	ENGOT Ov-43/MK7339-001	ATHENA
Trial identifier	NCT03038100	NCT03602859	NCT03737643	NCT03740165	NCT03522246
Histology	Epithelial	Epithelial	Epithelial	Epithelial	Epithelial
FIGO stage	III–IV	III–IV	III–IV	III–IV	III–IV
ECOG PS	0–2	0–1	0–2	0–1	0–2
Investigational drugs	Atezolizumab	Dorstarlimab Niraparib	Durvalumab Olaparib	Pembrolizumab Olaparib	Nivolumab Rucaparib
Control arm-chemotherapy phase	IV paclitaxel + IV carboplatin + IV bevacizumab + IV atezolizumab placebo	Arm 1: Standard of care chemotherapy + IV dorstarlimab placebo	Arm 1: IV paclitaxel + IV carboplatin + IV bevacizumab + IV durvalumab placebo	Arm 3: IV paclitaxel + IV carboplatin ± IV bevacizumab + IV pembrolizumab placebo	N/A
Control arm-maintenance phase	IV bevacizumab + IV atezolizumab placebo	Arm 1: IV dorstarlimab placebo + PO niraparib placebo	Arm 1: IV bevacizumab + IV durvalumab placebo + PO olaparib placebo	Arm 3: ± IV bevacizumab + IV pembrolizumab placebo + PO olaparib placebo	Arm D: IV nivolumab placebo + PO rucaparib placebo
Experimental arm (1)-chemotherapy phase	IV paclitaxel + IV carboplatin + IV bevacizumab +  IV atezolizumab (1200 mg, three-weekly)	Arm 2: Standard of care chemotherapy + IV dorstarlimab placebo	Arm 2: IV paclitaxel + IV carboplatin + IV bevacizumab + IV durvalumab	Arm 1: IV paclitaxel + IV carboplatin ±  IV bevacizumab + IV pembrolizumab (200 mg, three weekly)	N/A
Experimental arm (1)-maintenance phase	IV bevacizumab + IV atezolizumab (1200 mg, three-weekly)	Arm 2: IV dorstarlimab placebo + PO niraparib	Arm 2: IV bevacizumab + IV durvalumab + PO olaparib placebo	Arm 1: ± IV bevacizumab + IV pembrolizumab (200 mg, three-weekly) + PO olaparib (300 mg, twice-daily)	Arm A: IV nivolumab (four-weekly) + PO rucaparib (twice-daily)
Experimental arm (2)-chemotherapy phase	N/A	Arm 3: Standard of care chemotherapy + IV dorstarlimab	Arm 3/patients with tBRCAm: IV paclitaxel + IV carboplatin ± IV cevacizumab + IV durvalumab	Arm 2: IV paclitaxel + IV carboplatin ± IV bevacizumab + IV pembrolizumab	N/A
Experimental Arm (2)-maintenance phase	N/A	Arm 3: IV dorstarlimab + PO niraparib	Arm 3/patients with tBRCAm: ± IV bevacizumab + IV durvalumab + PO olaparib	Arm 2: ± IV bevacizumab + IV pembrolizumab (200 mg, three-weekly) + PO olaparib placebo	Arm B: IV nivolumab placebo + PO rucaparib (twice-daily)
Experimental arm (3)-maintenance phase	N/A	N/A	N/A	N/A	Arm C: IV nivolumab (four-weekly) + PO rucaparib placebo
Primary outcome	PFS in intention to treat (ITT) population PFS in programmed cell death-ligand 1 (PD-L1)-positive subpopulation OS in ITT population OS in PD-L1-positive population	PFS	PFS–in non-tBRCAm patients	PFS OS	PFS